Limits...
Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis.

Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu C, Jiang J - Sci Rep (2015)

Bottom Line: Overall, positive expression of WT1 was significantly associated with worse OS (metaHR = 1.48, 95% CI = 1.11-1.97) and DFS/RFS/PFS (metaHR = 2.14, 95% CI = 1.42-3.21).Subgroup analyses showed that WT1 positive expression could independently predict unfavorable DFS/RFS/PFS (metaHR = 1.86, 95%CI = 1.04-3.35).Further studies are needed to confirm the role of WT1 expression in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: 1] Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China [2] Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.

ABSTRACT
Though proposed as a promising target antigen for cancer immunotherapy, the prognostic value of Wilms' tumor 1 (WT1) in solid tumors remains inconclusive. Here, we report a systematic review and meta-analysis of the association between WT1 expression and prognosis in solid tumors. PubMed, Web of Science and Google Scholar were searched to identify studies exploring the impact of WT1 on clinical outcomes, including overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), relapse/recurrence-free survival (RFS) or progression-free survival (PFS), in solid cancer patients. Hazard ratio (HR) and 95% confidence interval (CI) were applied to assess the strength of these associations. Finally, a total of 29 eligible studies with 4090 patients were identified for qualitative analysis, and 22 studies with 3620 patients were enrolled for quantitative synthesis. Overall, positive expression of WT1 was significantly associated with worse OS (metaHR = 1.48, 95% CI = 1.11-1.97) and DFS/RFS/PFS (metaHR = 2.14, 95% CI = 1.42-3.21). Subgroup analyses showed that WT1 positive expression could independently predict unfavorable DFS/RFS/PFS (metaHR = 1.86, 95%CI = 1.04-3.35). In summary, our study suggests that WT1 may be a potential marker to predict DFS/RFS/PFS in solid tumor patients. Further studies are needed to confirm the role of WT1 expression in clinical practice.

Show MeSH

Related in: MedlinePlus

Funnel plot for the evaluation of potential publication bias in the impact of WT1 on overall survival (A), disease-specific survival (B) and disease-free survival/progression-free survival/relapse or recurrence-free survival (C) of patients with solid tumors.The funnel graph plots the log of HR against the standard error of the log of the HR (an indicator of sample size). The circles indicate the individual studies in the meta-analysis. The line in the center represents the metaHR.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4352850&req=5

f5: Funnel plot for the evaluation of potential publication bias in the impact of WT1 on overall survival (A), disease-specific survival (B) and disease-free survival/progression-free survival/relapse or recurrence-free survival (C) of patients with solid tumors.The funnel graph plots the log of HR against the standard error of the log of the HR (an indicator of sample size). The circles indicate the individual studies in the meta-analysis. The line in the center represents the metaHR.

Mentions: The shapes of the funnel plots did not reveal evidence of obvious asymmetry for OS (Figure 5A), DSS (Figure 5B) and DFS/RFS/PFS (Figure 5C) analyses, which was confirmed by the Begg's and Egger's tests (Table 2). The results of publication bias for studies using antigen-based methods to detect WT1 expression are shown in Table 3.


Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis.

Qi XW, Zhang F, Wu H, Liu JL, Zong BG, Xu C, Jiang J - Sci Rep (2015)

Funnel plot for the evaluation of potential publication bias in the impact of WT1 on overall survival (A), disease-specific survival (B) and disease-free survival/progression-free survival/relapse or recurrence-free survival (C) of patients with solid tumors.The funnel graph plots the log of HR against the standard error of the log of the HR (an indicator of sample size). The circles indicate the individual studies in the meta-analysis. The line in the center represents the metaHR.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4352850&req=5

f5: Funnel plot for the evaluation of potential publication bias in the impact of WT1 on overall survival (A), disease-specific survival (B) and disease-free survival/progression-free survival/relapse or recurrence-free survival (C) of patients with solid tumors.The funnel graph plots the log of HR against the standard error of the log of the HR (an indicator of sample size). The circles indicate the individual studies in the meta-analysis. The line in the center represents the metaHR.
Mentions: The shapes of the funnel plots did not reveal evidence of obvious asymmetry for OS (Figure 5A), DSS (Figure 5B) and DFS/RFS/PFS (Figure 5C) analyses, which was confirmed by the Begg's and Egger's tests (Table 2). The results of publication bias for studies using antigen-based methods to detect WT1 expression are shown in Table 3.

Bottom Line: Overall, positive expression of WT1 was significantly associated with worse OS (metaHR = 1.48, 95% CI = 1.11-1.97) and DFS/RFS/PFS (metaHR = 2.14, 95% CI = 1.42-3.21).Subgroup analyses showed that WT1 positive expression could independently predict unfavorable DFS/RFS/PFS (metaHR = 1.86, 95%CI = 1.04-3.35).Further studies are needed to confirm the role of WT1 expression in clinical practice.

View Article: PubMed Central - PubMed

Affiliation: 1] Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing, China [2] Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.

ABSTRACT
Though proposed as a promising target antigen for cancer immunotherapy, the prognostic value of Wilms' tumor 1 (WT1) in solid tumors remains inconclusive. Here, we report a systematic review and meta-analysis of the association between WT1 expression and prognosis in solid tumors. PubMed, Web of Science and Google Scholar were searched to identify studies exploring the impact of WT1 on clinical outcomes, including overall survival (OS), disease-specific survival (DSS), disease-free survival (DFS), relapse/recurrence-free survival (RFS) or progression-free survival (PFS), in solid cancer patients. Hazard ratio (HR) and 95% confidence interval (CI) were applied to assess the strength of these associations. Finally, a total of 29 eligible studies with 4090 patients were identified for qualitative analysis, and 22 studies with 3620 patients were enrolled for quantitative synthesis. Overall, positive expression of WT1 was significantly associated with worse OS (metaHR = 1.48, 95% CI = 1.11-1.97) and DFS/RFS/PFS (metaHR = 2.14, 95% CI = 1.42-3.21). Subgroup analyses showed that WT1 positive expression could independently predict unfavorable DFS/RFS/PFS (metaHR = 1.86, 95%CI = 1.04-3.35). In summary, our study suggests that WT1 may be a potential marker to predict DFS/RFS/PFS in solid tumor patients. Further studies are needed to confirm the role of WT1 expression in clinical practice.

Show MeSH
Related in: MedlinePlus